Angiopoietin-2 as a prognostic biomarker of major adverse cardiovascular events and all-cause mortality in chronic kidney disease

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Tsai, Yi Chun ^a,b,c   Lee, Chee Siong ^b   Chiu, Yi Wen ^b,c   Kuo, Hung Tien ^b,c   Lee, Su Chu ^b   Hwang, Shang Jyh ^a,b,c,d   Kuo, Mei Chuan ^a,b,c   Chen, Hung Chun ^b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DISEASE FREE SURVIVAL; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

AGED; ANGIOPOIETIN-2; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 84943142552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135181     Document Type: Article

References (33)

1. Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: A 21st century challenge in global health. Nephron Clin Pract 2011; 118: 269-277
2. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-2047 PMID: 16738019
3. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056 PMID: 15814534
4. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32 (Suppl 2) : S314-321 doi: 10.2337/dc09-S330 PMID: 19875572
5. Lilien MR, Groothoff JW. Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol 2009; 5: 229-235 doi: 10.1038/nrneph.2009.10 PMID: 19322188
6. Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 2003; 12: 933-941 PMID: 12783598
7. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: Evidence for network stabilization, cell survival and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213-223 PMID: 10068209
8. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2 ligands for the endothelial specific receptor tyrosine kinase Tie2. J Biol Chem 1998; 273: 18514-18521 PMID: 9660821
9. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002; 99: 11205-11210 PMID: 12163646
10. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355-2360 PMID: 15302795
11. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004; 43: 423-428 PMID: 15013125
12. David S, Kumpers P, Hellpap J, Horn R, Leitolf H, Haller H, et al. Angiopoietin-2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kidney Dis 2009; 53: 770-778 doi: 10.1053/j.ajkd. 2008.11.030 PMID: 19268412
13. Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med 2008; 40: 215-222 doi: 10.1080/07853890701779586 PMID: 18382887
14. Lorbeer R, Baumeister SE, Dörr M, Nauck M, Grotevendt A, Völzke H, et al. Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur J Heart Fail 2013; 15, 1327-1334 doi: 10.1093/eurjhf/hft117 PMID: 23901057
15. David S, Kumpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Böger SM, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 2571-2576 doi: 10.1093/ndt/gfq060 PMID: 20179005
16. Shroff RC, Price KL, Kolatsi-Joannou M, Todd AF, Wells D, Deanfield J, et al. Circulating angiopoietin- 2 is a marker for early cardiovascular disease in children on chronic dialysis. PLoS One 2013; 8: E56273 doi: 10.1371/journal.pone.0056273 PMID: 23409162
17. Molnar MZ, Kümpers P, Kielstein JT, Schiffer M, Czira ME, Ujszaszi A, et al. Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: A 4-year prospective case-cohort study. Transpl Int 2014; 27: 541-552 doi: 10.1111/tri.12293 PMID: 24628855
18. David S, John SG, Jefferies HJ, Sigrist MK, Kümpers P, Kielstein JT, et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 2012; 27: 1867-1872 doi: 10.1093/ndt/gfr551 PMID: 21976741
19. Tsai YC, Chiu YW, Tsai JC, Kuo HT, Lee SC, Hung CC, et al. Association of angiopoietin-2 with renal outcome in chronic kidney disease. PLoS One. 2014; 9: E108862 doi: 10.1371/journal.pone.0108862 PMID: 25279852
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 PMID: 10075613
21. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al. Cardiovascular outcomes and all-cause mortality: Exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48: 392-401 PMID: 16931212
22. Hwang SJ, Lin MY, Chen HC, Hwang SC, Yang WC, Hsu CC, et al. Increased risk of mortality in the elderly population with late-stage chronic kidney disease: A cohort study in Taiwan. Nephrol Dial Transplant 2008; 23: 3192-3198 doi: 10.1093/ndt/gfn222 PMID: 18450830
23. Lee JY, Miller EJ. Angiopoietin-2: A Key to Understanding Sepsis and Its Pulmonary Sequelae? J Pulm Respire Med 2014; 4: 172-179
24. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011; 39: 702-710 doi: 10.1097/CCM.0b013e318206d285 PMID: 21242795
25. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585 doi: 10.1038/nrc2894 PMID: 20651738
26. Chen JX, Zeng H, Reese J, Aschner JL, Meyrick B. Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model. Am J Physiol Heart Circ Physiol 2012; 302: 1003-1012
27. Chang FC, Lai TS, Chiang CK, Chen YM, Wu MS, Chu TS, et al. Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS One 2013; 8: E54668 doi: 10.1371/journal.pone.0054668 PMID: 23469160
28. Lorbeer R, Baumeister SE, Dörr M, Felix SB, Nauck M, Grotevendt A, et al. Angiopoietin-2, its soluble receptor Tie-2 and subclinical cardiovascular disease in a population-based sample. Heart 2015; 101: 178-184 doi: 10.1136/heartjnl-2014-306056 PMID: 25286927
29. Fiedler U, Augustin HG. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-558 PMID: 17045842
30. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-239 PMID: 16462802
31. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 2005; 314: 738-44 PMID: 15870388
32. Lemieux C, Maliba R, Favier J, Theoret JF, Merhi Y, Sirois MG. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005; 105: 1523-1530 PMID: 15498854
33. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin- 1, and angiopoietin-2 in diabetes: Implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27: 2918-2924 PMID: 15562207